Short-Term Effects of Intra-Articular Corticosteroid Injection on Knee Function in Juvenile Idiopathic Arthritis

July 11, 2026 updated by: Serdar Arslan, Necmettin Erbakan University

Short-Term Effects of Intra-Articular Corticosteroid Injection on Knee Function in Juvenile Idiopathic Arthritis: A Prospective Cohort Study

The purpose of this study is to evaluate the short-term clinical effects of intra-articular corticosteroid injections on knee joint functions in children and adolescents diagnosed with Juvenile Idiopathic Arthritis (JIA).

Patients who receive a corticosteroid injection into the knee joint as part of their routine medical treatment will be monitored prospectively. The study aims to assess changes in range of motion, functional status, and pain levels before the injection and during the early follow-up period after the procedure. This will help healthcare providers better understand the immediate benefits and functional outcomes of this treatment in youth sports and daily physical activities.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

17

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
      • Konya, Turkey (Türkiye)
        • Necmettin Erbakan University, Faculty of Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study population consists of pediatric patients diagnosed with Juvenile Idiopathic Arthritis (JIA) who present with active unilateral or bilateral knee joint involvement. Participants include both newly diagnosed individuals and those under regular follow-up at a tertiary medical center's outpatient clinic, all of whom required clinical knee intra-articular corticosteroid injection (IACI) as part of their routine medical management.

Description

Inclusion Criteria:

  • Patients diagnosed with juvenile idiopathic arthritis (JIA) according to standard criteria (arthritis with onset before the age of 16 years and duration longer than 6 weeks with no other identifiable cause).
  • Having unilateral or bilateral active knee joint arthritis.
  • Undergoing knee intra-articular corticosteroid injection (IACI) for the active knee joint involvement.
  • Provision of written informed consent by both patients and their caregivers.

Exclusion Criteria:

  • Presence of other chronic rheumatological diseases.
  • Initiation or discontinuation of systemic steroids, conventional disease-modifying anti-rheumatic drugs (DMARDs) (e.g., methotrexate, sulfasalazine), or biologic DMARDs (e.g., inhibitors of TNF, IL-1, or IL-6) within the 3 months before knee IACI and during the follow-up period.
  • History of severe adverse reactions to steroids.
  • Presence of neurological diseases.
  • History of lower extremity surgery.
  • Missing data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline in Pain Intensity
Time Frame: Baseline (T0), 2 weeks (T1), and 2 months (T2) post-injection
Pain intensity assessed at rest and during physical activity using a standard assessment scale.
Baseline (T0), 2 weeks (T1), and 2 months (T2) post-injection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Necmettin Erbakan University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2022

Primary Completion (Actual)

August 15, 2023

Study Completion (Actual)

August 15, 2023

Study Registration Dates

First Submitted

July 11, 2026

First Submitted That Met QC Criteria

July 11, 2026

First Posted (Actual)

July 16, 2026

Study Record Updates

Last Update Posted (Actual)

July 16, 2026

Last Update Submitted That Met QC Criteria

July 11, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2022/311

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe